Skip to main content
. 2018 Aug 20;8:12459. doi: 10.1038/s41598-018-31003-6

Figure 3.

Figure 3

Anti-GP Ebolavirus antibody responses. Anti-SUDV-GP (A,C) and anti-EBOV-GP (B,D) antibody endpoint titers were determined in immunized mice after prime (A,B) and after boost (C,D). Mice were immunized with 5 µg of DREP Ebolavirus constructs (D-GP-S, D-GP-Z, D-GP-S/Z; n = 12/group, D-GP-VP40-S, D-GP-VP40-Z; n = 6/group) or GP protein (P-S/Z; n = 6/group) and bled 21 days after the immunization and individual serum samples were assayed by ELISA using plates coated with SUDV or EBOV GP (A and B, respectively). In panels C and D, mice (n = 6/group) were primed as above and boosted on day 28 and blood was collected on day 49 individual serum samples were assayed by ELISA using plates coated with SUDV or EBOV GP (C,D, respectively). Statistical analysis was performed using Kruskal Wallis test followed by Dunn’s test for multiple comparisons, *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.001. Comparisons that were non significant are not indicated.